ASXL1 mutations in younger adult patients with acute myeloid leukemia: A study of the German-Austrian Acute Myeloid Leukemia Study Group

ASXL1 mutations in 6.1% of AML patients (103/1696)

ASXL1 mutations: clinical characteristics and outcome
- Males
- Elderly
- Secondary AML
- Low value of WBC
- Low value of lactate dehydrogenase (serum)
- Low values of BM and circulating blasts

Inferior* CRR, EFS and OS
*compared to ASXL1 wt

Distribution of ASXL1 mutations

ASXL1 mutations and cytogenetic risk groups
- Favorable: 10%
- Intermediate (normal karyotype): 40%
- Intermediate (other): 26%
- Adverse: 24%

ASXL1 mutations association with other gene mutations

Positive
- RUNX1
- IDH2 R140

Negative
- NPM1
- FLT3 ITD
- DNMT3A

ASXL1 and RUNX1 mutations (CR, %)

- ASXL1 mut, RUNX1 mut: 45.5
- ASXL1 mut, RUNX1 wt: 62.3
- ASXL1 wt, RUNX1 mut: 63.9
- ASXL1 wt, RUNX1 wt: 75.2

Paschka et al., Haematologica, 2015